中国冠心病二级预防研究——对合并糖尿病患者的干预结果分析  

China coronary secondary prevention study (CCSPS):outcomes from analysis of coronary heart disease patients with diabetes

作　　者：陆宗良[1] 杜保民 陈祚 武阳丰 于学海 赵宇程 

机构地区：[1]中国医学科学院中国协和医科大学阜外心血管病医院,北京100037 [2]血脂康调整血脂对冠心病二级预防研究协作组

出　　处：《中华心血管病杂志》2005年第12期1067-1070,共4页Chinese Journal of Cardiology

基　　金：国家"九五"医学科技攻关项目(96-906-02-10)

摘　　要：目的探讨血脂康胶囊对冠心病合并糖尿病患者的二级预防效果。方法对中国冠心病二级预防研究中的591例合并糖尿病的冠心病患者的干预结果进行统计分析。结果冠心病合并糖尿病患者的各类临床事件的发生率远高于无糖尿病史的冠心病患者。这部分患者经血脂康胶囊治疗后,冠心病事件可减少50.8%(P=0.0008);死亡事件可减少44.1%(P=0.0097);脑卒中、肿瘤、经皮冠状动脉介入术/结论合并糖尿病的冠心病患者较其他患者处于更高危状态,血脂康胶囊用于这部分患者的冠心病二级预防是有效的。Objective To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease （CHD） patients with diabetes. Methods We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang （0. 6 g, Bid） or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD. Results （ 1 ） The incidence of CHD events and that of death from CHD were reduced by 50. 8% （ P = 0. 0008 ） and by 44. 1% （ P = 0. 0246 ） in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% （P =0. 0151 ）. （2） The incidence of stroke, tumor, and PCI/CABG were decreased by 20. 2%. （3）The total mortality were lowered by 44. 1% in treatment group （P = 0. 0097）. Conclusion Xuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.

关 键 词：冠状动脉疾病 糖尿病 综合预防 血脂康 冠心病患者 糖尿病患者 二级预防 预防研究 中国 经皮冠状动脉介入术 

分 类 号：R541.4[医药卫生—心血管疾病] R587.1[医药卫生—内科学]